These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26284932)

  • 1. Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial.
    Ginsberg Y; Långström N; Larsson H; Lindefors N
    J Clin Psychopharmacol; 2015 Oct; 35(5):535-43. PubMed ID: 26284932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension.
    Ginsberg Y; Lindefors N
    Br J Psychiatry; 2012 Jan; 200(1):68-73. PubMed ID: 22075648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
    Konstenius M; Jayaram-Lindström N; Guterstam J; Beck O; Philips B; Franck J
    Addiction; 2014 Mar; 109(3):440-9. PubMed ID: 24118269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
    Levin FR; Evans SM; Brooks DJ; Kalbag AS; Garawi F; Nunes EV
    Drug Alcohol Depend; 2006 Feb; 81(2):137-48. PubMed ID: 16102908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study.
    Asherson PJ; Johansson L; Holland R; Bedding M; Forrester A; Giannulli L; Ginsberg Y; Howitt S; Kretzschmar I; Lawrie SM; Marsh C; Kelly C; Mansfield M; McCafferty C; Khan K; Müller-Sedgwick U; Strang J; Williamson G; Wilson L; Young S; Landau S; Thomson LDG
    Br J Psychiatry; 2023 Jan; 222(1):7-17. PubMed ID: 35657651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II).
    Asherson P; Johansson L; Holland R; Fahy T; Forester A; Howitt S; Lawrie S; Strang J; Young S; Landau S; Thomson L
    Trials; 2019 Dec; 20(1):663. PubMed ID: 31791384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
    World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
    Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
    Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Kotarski M; Spencer T
    J Clin Psychopharmacol; 2010 Oct; 30(5):549-53. PubMed ID: 20814332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.
    Ginsberg Y; Hirvikoski T; Grann M; Lindefors N
    Eur Arch Psychiatry Clin Neurosci; 2012 Dec; 262(8):705-24. PubMed ID: 22526730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.